We are live on ! Find out more
ADIL

Adial Pharmaceuticals

17 hedge funds and large institutions have $335K invested in Adial Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

425% more capital invested

Capital invested by funds: $63.8K → $335K (+$271K)

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

13% more funds holding

Funds holding: 1517 (+2)

3.87% more ownership

Funds ownership: 2.5%6.37% (+3.9%)

Holders
17
Holders Change
+2
Holders Change %
+13.33%
% of All Funds
0.2%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
3
Reduced
2
Closed
2
Calls
Puts
Net Calls
Net Calls Change

ADIL Hedge Fund Activity: Q2 2026 in Review

17 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q2 2026, worth a combined $335K — up 425% from $63.8K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ADIL positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $63.6K. The largest seller was Geode Capital Management, cutting an estimated $23.5K.

  • 17 institutional investors held Adial Pharmaceuticals (ADIL) as of Q2 2026, up from 15 in Q1 2026.
  • Funds reported $335K of Adial Pharmaceuticals stock for Q2 2026, up 425% quarter-over-quarter.
  • 4 funds opened new Adial Pharmaceuticals positions in Q2 2026 and 2 closed out, a net change of +2 holders.
  • The largest Adial Pharmaceuticals buyer in Q2 2026 was Jane Street, an estimated $63.6K added.
  • The largest Adial Pharmaceuticals seller in Q2 2026 was Geode Capital Management, an estimated $23.5K sold.

Based on aggregated 13F filings for Q2 2026.